Glutathione Research Overview (also known as GSH)
A tripeptide (glutamate-cysteine-glycine) serving as the body's primary intracellular antioxidant and redox buffer. Synthesized primarily in the liver, it neutralizes reactive oxygen species, supports liver phase II detoxification, processes heavy metals, and protects mitochondrial DNA. Studied for liver health, metabolic disease, immune function, and as a foundational layer supporting other research compounds.
What Is Glutathione?
Glutathione (GSH) is a tripeptide (γ-glutamyl-cysteinyl-glycine) and the most abundant intracellular antioxidant in the human body. Every cell produces it, but concentrations are highest in the liver — reflecting its central role in detoxification, heavy metal chelation, and phase II metabolic conjugation. Glutathione levels decline with age, disease, and chronic stress — a decline increasingly recognized as a contributor to aging-associated oxidative tissue damage and immune dysfunction.
Antioxidant Mechanisms
Glutathione protects cells through direct scavenging of reactive oxygen species, enzymatic antioxidant function as the cofactor for glutathione peroxidases, and regeneration of other antioxidants including vitamins C and E from their oxidized forms. The glutathione/oxidized glutathione (GSSG) ratio serves as a key indicator of cellular redox status.
Detoxification and Immune Applications
In the liver, glutathione conjugates electrophilic toxins — including acetaminophen metabolites, environmental toxins, and carcinogens — rendering them water-soluble for excretion. Glutathione is also required for optimal lymphocyte proliferation and natural killer cell cytotoxicity. Its decline with age contributes to immunosenescence, and restoration of glutathione levels has been shown in multiple studies to improve immune parameters in elderly subjects.
Quick Reference
| Literature-Reported Dose Range | 200-600 mg |
| Literature-Reported Frequency | 1-3x per week |
| Literature-Reported Cycle Length | 4-8 weeks |
| Literature-Reported Washout | 4 weeks between cycles recommended |
| Storage | Refrigerate at 2-8°C, protect from light |
| Sites Reported in Studies | IM: deltoid, gluteal | SubQ: abdomen | IV: clinical setting |
| Timing | Flexible timing, morning preferred by some |
Research Indications
Antioxidant Support
Master Antioxidant
Primary intracellular antioxidant found in virtually every cell. Neutralizes free radicals and reactive oxygen species.
Antioxidant Recycling
Regenerates oxidized vitamins C and E, extending their protective capacity.
Detoxification
Phase II Liver Support
Conjugates toxins, drugs, and heavy metals to water-soluble forms for excretion via bile and urine.
Heavy Metal Binding
Binds mercury, lead, arsenic, and cadmium for elimination.
Immune Function
Lymphocyte Support
Essential for T-cell proliferation and NK cell activity. Even moderate GSH changes profoundly affect immune function.
Neurological Health
Parkinson's Research
GSH is depleted in PD patients' substantia nigra. Clinical trials of IV and intranasal delivery show potential benefits.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| General support | 200-400 mg | 1-2x weekly | IM or IV |
| Detoxification | 400-600 mg | 2-3x weekly | IV |
| Neurological (research) | 1400 mg | 3x weekly | IV infusion |
Timing
Recommended administration window: flexible timing, morning preferred by some. Typical onset: benefits build over 4-8 weeks of consistent use.
Reported Research Timeline
01Week 1–2 (reported in cited studies): minimal noticeable effects initially
02Week 2–4 (reported in cited studies): some may notice improved energy or recovery
03Week 4–8 (reported in cited studies): potential improvements in target areas (skin, immunity, etc.)
04Effects are supportive and subtle - not dramatic overnight changes
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Injection site stinging/pain common if pH not properly buffered (should be pH 6.0-7.0)
IV carries anaphylaxis risk - clinical supervision recommended
Avoid during chemotherapy without oncologist approval
May worsen asthma symptoms
Avoid in pregnancy/breastfeeding - safety not established
Long-term high-dose use may deplete zinc
Seek Medical Attention If:
Allergic reaction: hives, swelling, difficulty breathing
Signs of liver problems: jaundice, dark urine
Severe injection site reactions
Worsening asthma symptoms
Peptide Interactions
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
BPC-157 upregulates the NO system and supports antioxidant enzyme activity; glutathione provides direct ROS scavenging. The combination supports tissue repair from both the circulatory (BPC-157) and redox (glutathione) dimensions.
Both affect mitochondrial redox state. Methylene Blue is a mild oxidizing agent at low doses; excessive glutathione could theoretically blunt its redox effects. Use at different times of day if co-administering.
ALA recycles oxidized glutathione back to the reduced (active) form, extending glutathione effectiveness. ALA + glutathione is a well-established antioxidant protocol in integrative medicine.
Quality Indicators
Verified Marker
Reduced Form (GSH) — Not Oxidized (GSSG)
Pharmaceutical-grade glutathione should specify reduced glutathione (L-glutathione reduced / GSH). Oxidized glutathione (GSSG) has minimal therapeutic utility. CoA should confirm the form.
Verified Marker
Purity ≥98% with CoA
Reputable suppliers provide HPLC purity certificates. Glutathione is a well-characterized tripeptide (MW 307.3 Da) — identity confirmation by MS is straightforward and should accompany any research-grade product.
Verified Marker
White Powder; Clear Solution Post-Reconstitution
Correct glutathione appears white to off-white as a lyophilized powder and forms a clear, colorless to faint-yellow solution. Significant browning or opacity indicates oxidation or contamination.
Quality Concern
Oxidized or Degraded Product
Glutathione is sensitive to light, heat, and air. Products without proper lyophilization, dark glass vials, or cold-chain shipping risk being largely oxidized GSSG rather than active GSH.
Quality Concern
No Storage Instructions or Ambient-Temperature Storage
IV/injectable glutathione requires refrigeration (2–8°C) after reconstitution. Oral products need a cool, dry environment. Any product shipped or stored at room temperature without temperature logging is a quality risk.
Research Citations
- High-dose intravenous glutathione in man: Pharmacokinetics and effects on cyst(e)ine in plasma and urine
Aebi, S., Assereto, R., Lauterburg, B.H., 1991, European Journal of Clinical Investigation - Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
Sian, J., Dexter, D.T., Lees, A.J., et al., 1994, Annals of Neurology - Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
Mischley, L.K., Lau, R.C., Shankland, E.G., Wilbur, T.K., Padowski, J.M., 2017, Journal of Parkinson's Disease - Glutathione and immune function
Droge, W., & Breitkreutz, R., 2000, Proceedings of the Nutrition Society - Glutathione synthesis
Lu, S.C., 2013, Biochimica et Biophysica Acta - Glutathione-responsive self-assembling peptide-coated Salmonella for antitumor therapy
Shen J, Zhu Y, Li T, 2026, J Control Release - Peptide AEDL and Glutathione Stimulates Root Development Nicotiana tabacum
Kononenko NV, Fedoreyeva LI, 2024, Int J Mol Sci - Improved efficacy of linear glutathione-peptide chaperon complexes on melanogenesis inhibition and transdermal delivery
Zheng J, Ma Q, Haider A, 2024, Bioorg Chem - Intracellular Restructured Reduced Glutathione-Responsive Peptide Nanofibers for Synergetic Tumor Chemotherapy
Guo WW, Zhang ZT, Wei Q, 2020, Biomacromolecules - Degradation of glutathione and glutathione conjugates in plants
Ito T, Ohkama-Ohtsu N, 2023, J Exp Bot
Research Focus
Antioxidant defense, Detoxification, Immune function, Liver protection, Anti-aging, Oxidative stress
Verified Vendors Carrying Glutathione
Frequently Asked Questions
What should researchers watch for with Glutathione?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Glutathione?
Week 1–2 (reported in cited studies): minimal noticeable effects initially
How is Glutathione typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →